Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
5.60
-0.10 (-1.75%)
At close: Jul 6, 2026, 4:00 PM EDT
5.52
-0.08 (-1.43%)
After-hours: Jul 6, 2026, 7:50 PM EDT
Nuvation Bio Employees
Nuvation Bio had 307 employees as of March 31, 2026. The number of employees increased by 34 or 12.45% compared to the same quarter last year.
Employees
307
Change
34
Growth
12.45%
Revenue / Employee
$465,948
Profits / Employee
-$475,550
Market Cap
1.95B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 307 | 34 | 12.45% |
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Sep 30, 2025 | 291 | 88 | 43.35% |
| Jun 30, 2025 | 278 | 111 | 66.47% |
| Mar 31, 2025 | 273 | 114 | 71.70% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Sep 30, 2024 | 203 | 150 | 283.02% |
| Jun 30, 2024 | 167 | 113 | 209.26% |
| Mar 31, 2024 | 159 | 106 | 200.00% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Sep 30, 2023 | 53 | -1 | -1.85% |
| Jun 30, 2023 | 54 | -31 | -36.47% |
| Mar 31, 2023 | 53 | -15 | -22.06% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Sep 30, 2022 | 54 | -4 | -6.90% |
| Jun 30, 2022 | 85 | 34 | 66.67% |
| Mar 31, 2022 | 68 | 30 | 78.95% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Recursion Pharmaceuticals | 600 |
| Lakefront Biotherapeutics NV | 558 |
| Syndax Pharmaceuticals | 298 |
| Monte Rosa Therapeutics | 187 |
| Stoke Therapeutics | 170 |
| Precigen | 160 |
| Absci | 140 |
NUVB News
- 4 hours ago - Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering - PRNewsWire
- 7 days ago - Nuvation Bio announces MHRA in UK approves MAA for taletrectinib - TheFly
- 7 days ago - Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom - PRNewsWire
- 10 days ago - Nuvation Bio prices upsized offering of $250M of convertible senior notes - TheFly
- 10 days ago - Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes - PRNewsWire
- 11 days ago - Nuvation Bio falls -10.1% - TheFly
- 11 days ago - Nuvation Bio files to sell $200M of Convertible Senior Notes due 2032 - TheFly
- 11 days ago - Nuvation Bio Announces Proposed Convertible Senior Notes Offering - PRNewsWire